Author

Angela Hamblin

University of Oxford

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:benchmark study· 1 Research Focus:cancer & tumor microenvironment· 1 Organism:human· 1 Approach:statistical model· 1 Assay:whole-genome sequencing· 1

Frequent Co-Authors

Alessandro LaganàiD· 1 shared Anjan ThakurtaiD· 1 shared Erin FlyntiD· 1 shared Evie Fitzsimons· 1 shared Hervé Avet‐LoiseauiD· 1 shared Jill CorreiD· 1 shared Karthik RamasamyiD· 1 shared Kwee YongiD· 1 shared

Activity by Year

2026-2026 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

Alessandro LaganàORCID

Mutual co-authors in cluster

Author profile →

1 paper

Recent·Most cited

Sequential acquisition of 1p31.1-p12 LOH and 1q Gain is a common double-hit event in relapsed/refractory myeloma

Naser Ansari‐Pour, Sarah Gooding, Mohammad H. Kazeroun, Seyed Alireza Hasheminasab, Evie Fitzsimons, Selina J Chavda, Alessandro Laganà, Erin Flynt, Udo C. T. Oppermann, Karthik Ramasamy, Kwee Yong, Angela Hamblin, Jill Corre, Hervé Avet‐Loiseau, Nikhil C. Munshi, , Anjan Thakurta

The paper identifies a therapy-driven genomic double-hit (1pCEN LOH and 1q gain) in relapsed/refractory myeloma, associated with poor prognosis and clonal expansion.

bioRxiv · May 21, 2026 · PreprintCancer Biology